Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414180 · ClinicalTrials.gov registry record · Phase 3
Bupropion SR for Treating Smokeless Tobacco Use
A Phase 3 study of Smokeless Tobacco, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
- 1
- Study location
NCT00414180 is a Phase 3 study of Smokeless Tobacco that has completed, run by Mayo Clinic. The registered enrollment target is 225 participants, above the 168-participant average among 3 other Smokeless Tobacco trials with a reported enrollment target (34% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00414180, a Phase 3 study of Smokeless Tobacco, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the efficacy and safety of bupropion SR for quitting tobacco in smokeless tobacco users.
Conditions Studied
Interventions
- DRUG Bupropion SR
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2003-08 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00414180
The ClinicalTrials.gov registry entry for NCT00414180 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 168-participant average among 3 other Smokeless Tobacco trials with a reported enrollment target (34% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smokeless Tobacco appearing as the primary indexed condition, and to 1 intervention - of which Bupropion SR is the first listed.
NCT00414180 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00414180 about?
NCT00414180 is a clinical study titled "Bupropion SR for Treating Smokeless Tobacco Use". To determine the efficacy and safety of bupropion SR for quitting tobacco in smokeless tobacco users.
What is the current status of trial NCT00414180?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2003-08. Estimated completion is 2005-05.
What conditions does trial NCT00414180 study?
This clinical trial studies the following conditions: Smokeless Tobacco.
What interventions are being tested in trial NCT00414180?
The interventions under investigation include: Bupropion SR (DRUG).
Who is sponsoring clinical trial NCT00414180?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00414180 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smokeless Tobacco
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Influence of Authorized Smokeless Tobacco Product Modified Risk Claims II: Laboratory Assessment of Sensory and Subjective Effects
RECRUITING · NA
-
Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure
ACTIVE NOT RECRUITING · Phase 1
-
Telephone Counseling for Snuff Users
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.